UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________
FORM 8-K
________________
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):February 22, 2005
ATHEROGENICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Georgia | 0-31261 | 58-2108232 |
| (State or other jurisdiction | (Commission | (I.R.S. Employer |
| of incorporation) | File Number) | Identification Number) |
8995 Westside Parkway
Alpharetta, GA 30004
(Address of principal executive offices)
Registrant's telephone number, including area code(678) 336-2500
_________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events.
On February 22, 2005, AtheroGenics, Inc. issued a press release to announce that the U.S. Food and Drug Administration has approved its proposed amendment to the ARISE Phase III clinical trial protocol for AGI-1067. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
The following exhibit is attached to this current report on Form 8-K as Exhibit 99.1.
Exhibit No. | Description | |
| 99.1 | - | Press Release dated February 22, 2005 |
____________________
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
ATHEROGENICS, INC. | ||
| Date: February 22, 2005 | By:MARK P. COLONNESE | |
| Mark P. Colonnese | ||
| Senior Vice President of Finance and | ||
| Administration and Chief Financial Officer |
____________________
3
EXHIBIT INDEX
Exhibit No. | Description | |
| 99.1 | - | Press Release dated February 22, 2005 |
4